Meet Darwin’s new Drug Review Tool! With this solution, Abarca clients and Darwin™ users may access real-time information on drug maintenance and will have full visibility of ongoing medication changes to health plan formularies. What were the challenges users were facing? Clients were experiencing a longer time period to complete the review process of formularies […]
Design Articles
Meet Darwin’s new Drug Review Tool
February 25th, 2022 by Abarca NewsBeneficial impacts of SGLT-2 Inhibitors on Cardiovascular Disease
February 24th, 2022 by Abarca NewsAfter several clinical trials associated with SGLT-2 inhibitors, this anti-diabetic drug class of medications is now linked to providing beneficial impacts on cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors, also known as SGLT2 inhibitors, are antidiabetic drug classes that exert their function by causing the kidneys to remove excess glucose through the urine. When utilized for the […]
Abarca brings awareness to American Heart Month: learn more about heart health
February 10th, 2022 by Abarca NewsEach February, Abarca joins the NHLBI and The Heart Truth® to celebrate American Heart Month by motivating Americans to adopt healthy lifestyles to prevent heart disease. Focusing on your heart health has never been more important. People with poor cardiovascular health are also at increased risk of severe illness from COVID-19. When we take care […]
Protect your respiratory health during the fungal spores season
January 27th, 2022 by Abarca NewsIn Puerto Rico, the months of February and March and September through November, are considered high risk for people with allergies and respiratory conditions. This is because the levels of allergens such as fungi, and pollens in the outdoor air increase (PR fungal spore season). These fungal spores can trigger respiratory complications in sensitive individuals. […]
Mobile solutions: A better way in member experience
January 25th, 2022 by GabrielleThe healthcare industry is becoming increasingly digital–particularly when it comes to providing resources for patients. At Abarca, we say it’s about time. We have always operated under the belief that smarter technology and a better member experience are critical to improving adherence and outcomes, lowering costs, and making healthcare better for everyone. Through AbarcaMX, our […]
Antiviral treatments for mild-moderate COVID-19: what you need to know
January 24th, 2022 by GabrielleAs we close out the second year of the COVID-19 pandemic, it is easy to see that we are in a very different place in terms of testing and treatments than we were in 2020. In particular, there are now a handful of antiviral drugs available to treat mild-moderate COVID-19. Here’s what you need to […]
Learn more: fad diets and ulcerative colitis
January 9th, 2022 by GabrielleIt seems like fad diets are everywhere. But, despite what we see on social media, it is important to remember that not every eating trend is healthy for everybody. For example, if you have ulcerative colitis (UC)–a condition that causes inflammation and ulcers in the lining of the large intestine–certain foods can trigger a flare […]
Welcome Serge Perras, Chief Information Officer, and Nicole Bulochnik, VP Drug Pricing!
January 1st, 2022 by GabrielleWe are thrilled to announce that we have added two new Abarcans to the Senior Leadership Team! Serge Perras has joined as our Chief Information Officer, bringing a solid track record of driving digital transformation across the insurance, financial, healthcare, telecommunications, and other industries. Most recently, he served as the Chief Technology Officer for an […]
Learn more about the thyroid gland & how it affects your health
January 1st, 2022 by Abarca NewsJanuary is here, bringing new year goals and opportunities. However, one of your biggest goals this month should be to check your thyroid health. According to the American Thyroid Association (ATA), more than 12% of the U.S population alone will develop a thyroid condition during their lifetime, up to 60% of those with thyroid disease […]
Abarca guarantees a commercial plan’s drug trend with Assura — our new financial model
December 16th, 2021 by Abarca NewsTHE CHALLENGE Plan sponsors are currently experiencing a high degree of volatility in drug spend, largely driven by expensive specialty medications. These drugs often account for less than 2% of all claims¹, but can represent more than 50% of total spend². This challenge is likely to get worse: Increasing numbers of high-cost therapies are expected […]